Intraoperative guidance in parathyroid surgery using near-infrared fluorescence imaging and low-dose Methylene Blue
- PMID: 25958068
- PMCID: PMC4603995
- DOI: 10.1016/j.surg.2015.03.027
Intraoperative guidance in parathyroid surgery using near-infrared fluorescence imaging and low-dose Methylene Blue
Abstract
Background: Identification of diseased and normal parathyroid glands during parathyroid surgery can be challenging. The aim of this study was to assess whether near-infrared (NIR) fluorescence imaging using administration of a low-dose Methylene Blue (MB) at the start of the operation could provide optical guidance during parathyroid surgery and assist in the detection of parathyroid adenomas.
Methods: Patients diagnosed with primary hyperparathyroidism planned for parathyroidectomy were included. Patients received 0.5 mg/kg MB intravenously directly after start of anesthesia. During the operation, NIR fluorescence imaging was performed to identify parathyroid adenomas. Imaging results were compared with a previous published feasibility study in which 12 patients received MB after intraoperative identification of the adenoma.
Results: A total of 13 patients were included in the current study. In 10 of 12 patients with a histologically proven adenoma, the adenoma was fluorescent. Mean signal to background ratio was 3.1 ± 2.8. Mean diameter of the resected lesions was 17 ± 9 mm (range 5-28 mm). Adenomas could be identified up to 145 minutes after administration, which was the longest timespan until resection. Interestingly, in 3 patients, a total of 6 normal parathyroid glands (median diameter 2.5 mm) with a signal to background ratio of 1.8 ± 0.4 were identified using NIR fluorescence imaging.
Conclusion: Early administration of low-dose MB provided guidance during parathyroidectomy by identifying both parathyroid adenomas and normal parathyroid glands. In patients in whom difficult identification of the parathyroid adenoma is expected or when normal glands have to be identified, the administration of MB may improve surgical outcome.
Copyright © 2015 Elsevier Inc. All rights reserved.
Conflict of interest statement
Quirijn R.J.G. Tummers, M.D.: Nothing to declare
Abbey Schepers, M.D., Ph.D.: Nothing to declare
Jaap F. Hamming, M.D., Ph.D.: Nothing to declare
J. Kievit, M.D., Ph.D.: Nothing to declare
John V. Frangioni, M.D., Ph.D.: FLARE™ technology is owned by Beth Israel Deaconess Medical Center, a teaching hospital of Harvard Medical School. Dr. Frangioni has started three for-profit companies, Curadel, Curadel ResVet Imaging, and Curadel Surgical Innovations, which has optioned FLARE™ technology for potential licensing from Beth Israel Deaconess Medical Center.
Cornelis J.H. van de Velde, M.D., Ph.D.: Nothing to declare
Alexander L. Vahrmeijer, M.D., Ph.D.: Nothing to declare
Figures
References
-
- Fraser WD. Hyperparathyroidism. Lancet. 2009 Jul 11;374(9684):145–58. - PubMed
-
- Phillips CD, Shatzkes DR. Imaging of the parathyroid glands. Semin Ultrasound CT MR. 2012 Apr;33(2):123–9. - PubMed
-
- Han N, Bumpous JM, Goldstein RE, Fleming MM, Flynn MB. Intra-operative parathyroid identification using methylene blue in parathyroid surgery. Am Surg. 2007 Aug;73(8):820–3. - PubMed
-
- Harrison BJ, Triponez F. Intraoperative adjuncts in surgery for primary hyperparathyroidism. Langenbecks Arch Surg. 2009 Sep;394(5):799–809. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
